Quality of life after prostate cancer treatments in patients comparable at baseline

van Tol-Geerdink, J J; Leer, J W H; van Oort, I M; van Lin, E J N T; Weijerman, P C; Vergunst, H; Witjes, J A; Stalmeier, P F M
May 2013
British Journal of Cancer;5/14/2013, Vol. 108 Issue 9, p1784
Academic Journal
Background:Previous studies on the effects of different prostate cancer treatments on quality of life, were confounded because patients were not comparable. This study examined treatment effects in more comparable groups.Methods:From 2008-2011, 240 patients with localised prostate cancer were selected to be eligible for both radical prostatectomy (RP) and external beam radiotherapy (EBRT). Brachytherapy (BT) was a third option for some. Health-related quality of life was measured by expanded prostate cancer index composite (EPIC) up to 12 months after treatment.Results:In the sexual domain, RP led to worse summary scores (P<0.001) and more often to a clinically relevant deterioration from baseline than BT and EBRT (79%, 33%, 34%, respectively). In the urinary domain, RP also led to worse summary scores (P=0.014), and more deterioration from baseline (41%, 12%, 19%, respectively). Only on the irritative/obstructive urinary scale, more BT patients (40%) showed a relevant deterioration than RP (17%) and EBRT patients (11%). In the bowel domain, the treatment effects did not differ.Conclusion:This study provides a more unbiased comparison of treatment effects, as men were more comparable at baseline. Our results suggest that, for quality of life, radiotherapy is as least as good an option as RP for treating localised prostate cancer.


Related Articles

  • Management of Urinary Incontinence after Prostate Cancer Treatment and Urethroplasty. McCammon, Kurt A. // AUANews;Apr2015, Vol. 20 Issue 4, p8 

    The article discusses the onset of urethral stricture or bladder neck contracture complications in prostate cancer patients treated with combined brachytherapy and external beam radiation therapy. It is noted that preoperative planning is necessary given the resulting urinary incontinence rates...

  • Adaptation and validation of the Spanish version of the Patient-Oriented Prostate Utility Scale (PORPUS). Ávila, Mónica; Pardo, Yolanda; Castells, Manel; Ferrer, Ferran; Boladeras, Ana; Pera, Joan; Prada, Pedro; Guix, Benjamin; Paula, Belen; Hernandez, Helena; Pont, Angels; Alonso, Jordi; Garin, Olatz; Bremner, Karen; Krahn, Murray; Ferrer, Montse // Quality of Life Research;Nov2014, Vol. 23 Issue 9, p2481 

    Objective: The Patient-Oriented Prostate Utility Scale (PORPUS) is a combined profile and utility-based quality of life measure for prostate cancer patients. Our objectives were to adapt the PORPUS into Spanish and to assess its acceptability, reliability, and validity. Methods: The PORPUS was...

  • The best method for dose escalation: Prostate brachytherapy. Morton, Gerard // Canadian Urological Association Journal;Jun2012, Vol. 6 Issue 3, p196 

    The author discusses the role of radiation therapy dose in the treatment of prostate cancer. He informs that external beam radiotherapy dose increases the biochemical control rate to about 10 percent in five years and also mentions that brachytherapy is a safe method of dose escalation. He...

  • Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position. Loblaw, D. Andrew // Canadian Urological Association Journal;Jun2012, Vol. 6 Issue 3, p199 

    The author discusses how increase in the dose of radiation therapy can affect the treatment of prostate cancer. He informs that external beam radiotherapy dose when given in accurate and precise way can give better outcomes and can lower cost and also mentions that brachytherapy is a safe method...

  • Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer. Bosco, Jaclyn L. F.; Halpenny, Barbara; Berry, Donna L. // Health & Quality of Life Outcomes;2012, Vol. 10 Issue 1, p123 

    Background: Men diagnosed with localized prostate cancer (LPC) can choose from multiple treatment regimens and are faced with a decision in which medical factors and personal preferences are important. The Personal Patient Profile-Prostate (P3P) is a computerized decision aid for men with LPC...

  • Focal therapy in prostate cancer: the current situation. Jácome-Pita, F. X.; Sánchez-Salas, R.; Barret, E.; Amaruch, N.; Gonzalez-Enguita, C.; Cathelineau, X. // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    Prostate cancer is one of the most significant pathologies in the field of urology. The adoption of screening strategies and improvements in biopsies have resulted in an increase in early-stage tumour detection. Radical global therapies provide very good oncological results in localised prostate...

  • Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer. Osmonov, Daniar K.; Aksenov, Alexey V.; Boller, Annkathrin; Kalz, Almut; Heimann, Diana; Janssen, Isa; Jünemann, Klaus-Peter // Advances in Urology;2014, p1 

    Background. Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. Since 2004 we have been developing therapeutic possibilities for these patients. Methods. We retrospectively analyzed a cohort of 41 patients...

  • Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. Li, Xuesong; Fang, Dong; Cooperberg, Matthew; Whitson, Jared; Lue, Tom; Zhou, Liqun; Shinohara, Katsuto // World Journal of Urology;Aug2014, Vol. 32 Issue 4, p1061 

    Objective: To investigate variation in the International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. Methods: From January 2004 to November 2009, 524 consecutive patients underwent prostate brachytherapy either alone or in combination with external beam radiation...

  • Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer. Takeda, Ken; Jingu, Keichi; Koto, Masashi; Fujimoto, Keisuke; Narazaki, Kakutaro; Kubozono, Masaki; Saito, Hideo; Yamada, Shigeyuki; Mitsuduka, Kohji; Ishidoya, Shigeto; Ariga, Hisanori; Arai, Yoichi; Yamada, Shogo // Tohoku Journal of Experimental Medicine;Jan2011, Vol. 223 Issue 1, p55 

    Prostate cancer is one of the common cancers in the world. In Japan, prostate brachytherapy (PB) with iodine-125 has become a treatment option for localized prostate cancer since 2003. Nevertheless, severe acute urinary toxicity (AUT) remains as one of the intractable side effects. We assessed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics